FDA's Plausible Mechanism Framework streamlines individualized therapy approvals for ultra-rare diseases.

The chondrosarcoma market is anticipated to increase during the forecast period (2026--2036), owing to improved diagnosis, treatment advancements, increased awareness, the launch of emerging therapies ...

Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 1:20 PM ESTCompany ParticipantsTom Frohlich ...

Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; ...

It also allowed the team to diagnose the younger of the pair with acromesomelic dysplasia, Maroteaux type (AMDM), a rare genetic disorder affecting the growth of bones. This is the earliest evidence ...

Pet parents are familiar with various cat breeds that top the "Most Popular" list, such as the Ragdoll, Maine Coon, Persian, ...

For too long, the promise of personalized therapies has been tantalizingly close, yet frustratingly out of reach for ...

An estimated 170,000 Australians were diagnosed with cancer in 2025. Many people know the causes of cancer are partly genetic. But how do your genes, which contribute so much of what makes you you, ...

The FDA has sketched out its new regulatory pathway to market for individualised therapies that treat ultra-rare diseases, based on a 'plausible mechanism' premise.

Neoadjuvant pembrolizumab (3 doses) in stage I–III disease yielded a 71% pCR rate and only one melanoma-specific survival event at 3 years post-resection. Experts discuss the SWOG S1512 trial of ...

Collectors are back on the hunt, racing to secure rare cultivars and bold variegated leaves before someone else claims them. Specialty nurseries tease limited preorders, ... Read moreThe post Plant ...